Neutrophil-to-lymphocyte ratio predicts overall survival of patients with combined hepatocellular cholangiocarcinoma

9Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

Abstract

The neutrophil-to-lymphocyte ratio (NLR) has been regarded as a prognostic factor in various types of cancer. The present study aimed to identify the association between NLR and combined hepatocellular cholangiocarcinoma (cHCC-CC) in patients who underwent surgical resection. The present study retrospectively reviewed 59 patients who were diagnosed with cHCC-CC and treated with surgical resection between January 2000 and October 2014 at the Department of Hepatobiliary and Pancreatic Surgery at Sun Yat-sen University Cancer Center (Guangzhou, China). The patients were divided into two groups: NLR≤2.75 and NLR>2.75. Patients with stage I and II or stage III and IV disease were classified into early- and advanced-stage groups, respectively, according to the Tumor-Node-Metastasis (TNM) staging system. Overall survival time (OS) was estimated using the Kaplan-Meier method. Univariate and multivariate Cox regression models were used to evaluate the prognostic value of NLR. The NLR value was significantly higher in the HCC advanced-stage group compared with that in the HCC early-stage group according to the TNM staging system (3.19 vs. 2.00; P=0.001). The median survival time was 83.6 months in the NLR≤2.75 group and 15 months in the NLR>2.75 group (P=0.004). Upon multivariate analysis, NLR>2.75 was an independent prognostic factor for poor cHCC-CC outcomes. Overall, the easily evaluated pre-treatment NLR may be an independent prognostic factor for patients with cHCC-CC treated by surgical resection.

References Powered by Scopus

Inflammation and cancer

12679Citations
N/AReaders
Get full text

Cancer-related inflammation

9195Citations
N/AReaders
Get full text

Time-dependent ROC curves for censored survival data and a diagnostic marker

2141Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Feasibility and safety of nivolumab in advanced hepatocellular carcinoma: real-life experience from three German centers

38Citations
N/AReaders
Get full text

The Functional Roles of Immune Cells in Primary Liver Cancer

22Citations
N/AReaders
Get full text

Competing risk analyses of overall survival and cancer-specific survival in patients with combined hepatocellular cholangiocarcinoma after surgery

18Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

He, C., Mao, Y., Lao, X., Li, S., & Lin, X. (2018). Neutrophil-to-lymphocyte ratio predicts overall survival of patients with combined hepatocellular cholangiocarcinoma. Oncology Letters, 15(4), 4262–4268. https://doi.org/10.3892/ol.2018.7882

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 2

40%

Researcher 2

40%

Professor / Associate Prof. 1

20%

Readers' Discipline

Tooltip

Medicine and Dentistry 4

67%

Biochemistry, Genetics and Molecular Bi... 1

17%

Nursing and Health Professions 1

17%

Save time finding and organizing research with Mendeley

Sign up for free